An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off.

This study is not recruiting patients in the United States.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Entacapone

Criteria

Inclusion Criteria:

• Attended the Phase IIb study

• Able to fill out the patient diary

Exclusion Criteria:

• Serious heart, pulmonary, renal, hepatic or gastrointestinal disease

• Dementia symptoms

• Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply.